The long-term commercial outlook for the traditional Lysosomal Alpha Glucosidase Market faces healthy disruption from the rapid maturation of in-vivo gene addition technologies. While chronic enzyme replacement therapy remains the current gold standard of care, it requires life-long bi-weekly clinic visits, presenting a significant burden to patients and healthcare budgets alike. In response,...